[(89)Zr]Zr-DFO-girentuximab and [(18)F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma

PURPOSE: Watchful waiting (WW) can be considered for patients with metastatic clear-cell renal cell carcinoma (mccRCC) with good or intermediate prognosis, especially those with <2 International Metastatic RCC Database Consortium criteria and ≤2 metastatic sites [referred to as watch and wait (“W...

Descripción completa

Detalles Bibliográficos
Autores principales: Verhoeff, Sarah R., Oosting, Sjoukje F., Elias, Sjoerd G., van Es, Suzanne C., Gerritse, Sophie L., Angus, Lindsay, Heskamp, Sandra, Desar, Ingrid M.E., Menke-van der Houven van Oordt, C. Willemien, van der Veldt, Astrid A.M., Arens, Anne I.J., Brouwers, Adrienne H., Eisses, Bertha, Mulders, Peter F.A., Hoekstra, Otto S., Zwezerijnen, Gerben J.C., van der Graaf, Winette T.A., Aarntzen, Erik H.J.G., Oyen, Wim J.G., van Herpen, Carla M.L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Precision Medicine and Imaging
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890134/
https://www.ncbi.nlm.nih.gov/pubmed/36394882
http://dx.doi.org/10.1158/1078-0432.CCR-22-0921

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890134/
https://www.ncbi.nlm.nih.gov/pubmed/36394882
http://dx.doi.org/10.1158/1078-0432.CCR-22-0921

Ejemplares similares